SemBioSys cuts jobs, plans company sale or shutdown

Canadian biotech company SemBioSys Genetics is exploring its strategic alternatives, including a corporate sale or merger, a strategic transaction for either insulin or Apo, an asset sale, a significant restructuring and recapitalization or a wind down of the company's operations. According to a release, the company has already laid off an unspecified number of employees. SemBioSys has been using patented plant seed, oil body and expression technology platforms to develop biosimilar drug candidates and proteins. SemBioSys release

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.